Mandate

Vinge has advised Magle Chemoswed Holding AB in connection with its listing on Nasdaq First North Growth Market

Vinge has provided capital markets and transaction advice in connection with Magle Chemoswed Holding AB’s listing on Nasdaq First North Growth Market.

The prospectus was published on 2 June 2020 and trading on Nasdaq First North Growth Market was commenced on 30 June 2020. The offer related to 25 per cent of the total number of existing shares and following full subscription the value of the offer amounted to SEK 50 million.

Magle Chemoswed is an international contract development and manufacturing company and also develops its own product portfolio based on the company’s technology platforms. The company owns its manufacturing and development facilities in Malmö and works in relation to the development and manufacture of pharmaceuticals and medical devices on a contract basis. On 31 March 2020, the company had 70 employees and in 2019, the net turnover amounted to approximately SEK 128 million.

Vinge’s team consisted primarily of Kristian Ford, Christian Lindhé, Martin Svanberg, Sophia Reutercrona, Niklas Törnell, Tilda Hall, Daniel Melander Björner and Johan Cederblad.

Related

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of their production facility in Uppsala to Ofichem. The Uppsala site specializes in small-scale, early-phase development work.
August 13, 2025

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025